Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00329355
Status:
COMPLETED
Last Update Posted:
2017-01-23
First Post:
2006-05-22
Brief Title:
Menstrual Migraine Treatment With TREXIMET Formerly Known as TREXIMA
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Single Migraine Attack Placebo-controlled Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima Sumatriptan SuccinateNaproxen Sodium Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to determine efficacy of TREXIMET sumatriptannaproxen sodium formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine
Detailed Description:
A randomized double-blind single migraine attack placebo-controlled parallel-group multicenter study to evaluate the efficacy and tolerability of TREXIMA sumatriptan succinatenaproxen sodium tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea TREXIMET
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None